Fucosidosis is an autosomal recessive lysosomal storage disease caused by biallelic variants in the FUCA1 gene. Alpha-L-fucosidase deficiency prevents the degradation of oligosaccharides, glycoproteins, and glycolipids containing fucose, leading to their progressive accumulation in lysosomes. This accumulation causes multisystem involvement, especially neurological, with developmental delay, psychomotor regression, coarse facial features, recurrent respiratory infections, and musculoskeletal abnormalities.
Fucosidosis
The FUCA1 gene encodes the lysosomal enzyme alpha-L-fucosidase, responsible for removing terminal L-fucose residues present in complex molecules such as glycoproteins, glycolipids, and oligosaccharides. This function allows for the complete cellular recycling of fucosylated compounds within lysosomes. When enzymatic activity is markedly reduced or absent, these compounds are not degraded properly and accumulate in multiple tissues.
Cellular damage derived from lysosomal storage predominantly affects the central nervous system, although it can also compromise bones, skin, the respiratory system, heart, eyes, and liver. The disease is considered a continuous spectrum, although it has classically been divided into a type I form, with early onset and severe progression, and a type II form, with later onset and slower progression. Inheritance is autosomal recessive: an affected person inherits a pathogenic variant from each parent. It is an ultrarare disease, with an estimated incidence of less than 1 in 200,000 live births, although higher incidences have been described in Italy, Cuba, and some Hispanic-American populations due to familial aggregation or founder effect.
Symptoms
The clinical presentation is variable. Severe forms usually begin during the first year of life or in early childhood, with developmental delay, psychomotor regression, intellectual disability, initial hypotonia that may evolve to spasticity, epileptic seizures, and progressive loss of motor and language skills. Coarse facial features, short stature, recurrent respiratory infections, hepatosplenomegaly, multiple dyostosis, kyphoscoliosis, joint contractures, and feeding problems are common. In milder forms, onset may occur in childhood or adolescence, with slower progression and the appearance of skin lesions such as telangiectasias or angiokeratomas; ocular, auditory, or cardiac involvement may also be observed.
Disease management
There is no approved curative treatment or enzyme replacement therapy available for fucosidosis. Management is mainly multidisciplinary and supportive, aimed at preserving function, treating complications, and improving quality of life. It may include physical therapy, occupational therapy, and speech therapy, spasticity and pain control, seizure management, nutritional and respiratory support, management of recurrent infections, and follow-up by neurology, rehabilitation, pulmonology, cardiology, ophthalmology, otorhinolaryngology, and orthopedics. Hematopoietic stem cell transplantation has been considered in highly selected cases diagnosed early, before significant neurological deterioration, although experience is limited and results are variable. Family genetic identification allows for genetic counseling, carrier testing, and prenatal or preimplantation diagnosis when appropriate.
Genes analyzed
Bibliography
Pekdemir B, Bechelany M, Karav S. Fucosidosis: A Review of a Rare Disease. Int J Mol Sci. 2025 Jan 3;26(1):353.
Puente-Ruiz N, Ellis I, Bregu M, et al. Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations. Mol Genet Metab Rep. 2023 Sep 27;37:101009.
Gowda VK, Srinivasan VM, Vegda H, et al. Fucosidosis with Pathogenic Variant in FUCA1 Gene. Indian J Pediatr. 2020 Oct;87(10):867-868.
Stepien KM, Ciara E, Jezela-Stanek A. Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series. Genes (Basel). 2020 Nov 22;11(11):1383.
